The Gabrail Cancer Center currently has many Clinical Trial opportunities. For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or email CSmith@GabrailCancerCenter.com.
Randomized, Non-Comparative Phase 1/2 Study of NUV-422 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative (HR+HER2-) Advanced Breast Cancer (aBC)
Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance on First Line Palbociclib Plus Aromatase Inhibitor Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
A Phase 1b Clinical Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, as a Chemoprotection Agent in Patients with TP53-mutated, HER2 Negative Stage IIa – IIIb Breast Cancer Receiving Neoadjuvant Chemotherapy